Dr. Devalingam Mahalingam, M.D.
What this data tells you about Dr. Mahalingam
Dr. Devalingam Mahalingam is an internal medicine specialist in Chicago, IL, with 17 years of NPI registration. Based on federal Medicare data, Dr. Mahalingam performed 29,071 Medicare services across 1,185 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mahalingam received a total of $297,161 from 14 pharmaceutical and/or device companies across 283 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mahalingam is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
6,120 | $38 | $170 |
| Pembrolizumab injection (Keytruda) | 5,400 | $41 | $165 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
4,350 | $0 | $7 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
2,516 | $20 | $244 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
2,490 | $36 | $134 |
| Denosumab injection (Prolia/Xgeva) | 1,980 | $19 | $58 |
| Bevacizumab biosimilar injection, 10 mg An injection of bevacizumab-awwb, a biosimilar medication, administered in a 10 mg dose. |
1,712 | $23 | $194 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
991 | $3 | $174 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
596 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 590 | $1 | $76 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
263 | $4 | $10 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
258 | $2 | $7 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
186 | $108 | $940 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
185 | $13 | $143 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
168 | $86 | $821 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
128 | $99 | $323 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 111 | $3 | $105 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
109 | $147 | $434 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
106 | $70 | $219 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
96 | $2 | $16 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
96 | $2 | $94 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
89 | $17 | $129 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
82 | $53 | $410 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
67 | $23 | $215 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
60 | $60 | $326 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
56 | $12 | $88 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
55 | $24 | $203 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
44 | $54 | $464 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
31 | $213 | $1,618 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
29 | $46 | $393 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
26 | $1 | $4 |
| New patient office visit, complex (60-74 min) | 20 | $176 | $625 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
18 | $75 | $175 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
17 | $1 | $7 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
13 | $8 | $20 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
13 | $129 | $505 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
All-time payments by company (2018-2024) ›
Associated products mentioned in payments ›
The majority of payments (81%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in internal medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for internal medicine in IL.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mahalingam is a mixed practice specialist, with above-average Medicare volume (top 1% in IL), with speaking/promotional industry engagement in the top 0% of IL peers, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mahalingam experienced with daratumumab injection (darzalex)?
Does Dr. Mahalingam receive payments from pharmaceutical companies?
How do Dr. Mahalingam's costs compare to other internal medicine physicians in Chicago?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology